EXHIBIT 31.1

       CERTIFICATIONS UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Georges Benarroch, certify that:

1.       I have reviewed this annual report on Form 10-KSB of Kyto Biopharma,
Inc.;

2.       Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.       Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4.       I am responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
small business issuer and have:

         a)       designed such disclosure controls and procedures to ensure
         that material information relating to the small business issuer,
         including its consolidated subsidiary, is made known to us by others
         within those entities, particularly during the period in which this
         report is being prepared;

         b)       evaluated the effectiveness of the small business issuer's
         disclosure controls and procedures as of a date within 90 days prior to
         the filing date of this report (the "Evaluation Date"); and

         c)       presented in this annual report our conclusions about the
         effectiveness of the disclosure controls and procedures based on our
         evaluation as of the Evaluation Date;

5.       I have disclosed, based on our most recent evaluation, to the small
business issuer's auditors and the audit committee of registrant's board of
directors (or persons performing the equivalent function):

         a)       all significant deficiencies in the design or operation of
         internal controls which could adversely affect the small business
         issuer 's ability to record, process, summarize and report financial
         data and have identified for the registrant's auditors any material
         weaknesses in internal controls; and

         b)       any fraud, whether or not material, that involves management
         or other employees who have a significant role in the small business
         issuer's internal controls; and

6.       I have indicated in this report whether or not there were significant
changes in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.

Date:  June 30, 2008


                                 By:    /s/ Georges Benarroch
                                        ----------------------------------
                                        Georges Benarroch
                                        President, Chief Executive Officer
                                        and Acting Chief Financial Officer